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Natural history of HCV related chronic hepatitis is inﬂuenced and modiﬁed by many factors: virus features, coinfections and
host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of intracellular
metabolic derangements (i.e., insulin resistance) might contribute to accelerate the rate of progression to cirrhosis and eventually
the occurrence of hepatocellular carcinoma (HCC) and death. Likely, direct interplays between virus genotype and host genetic
background might be hypothesized at this level. Morbidity and mortality in cirrhosis is primarily associated with complications of
livercirrhosis(ascites,hepaticencephalopathy,jaundice,andgastroesophagealbleeding)andHCCoccurrence.Thereforethemain
goaloftherapyistoclearviralinfectionanddecreaselivernecro-inﬂammationthatdirectlyrelatestodevelopmentofcirrhosisand
HCC. Among patients treated with Interferon-based therapy, those with sustained viral response showed a signiﬁcant reduction
of progression to cirrhosis and development of HCC. However, a residual risk of hepatocellular carcinoma still remains indicating
the need for careful follow-up using ultrasonography every six months in cirrhotic patients, even in those showing persistently
normal ALT and undetectable HCV RNA levels after antiviral therapy.
1.Introduction
ThenaturalhistoryofHCVinfectionisusuallycharacterized
by the transition from no perceivable acute to chronic infec-
tion, which may progress from a long-lasting asymptomatic
condition up to a decompensated hepatic disease and/or
hepatocellular carcinoma (HCC) development, which rep-
resents the main cause of liver-related death and liver
transplantation in the Western World [1–5]( Figure 1). One
hundred seventy million of people are infected worldwide,
more than 30 million are aﬀected by cirrhosis, and the
incidence of HCC is about 1-2 million new cases/year. The
actual estimated incidence is markedly decreased, and this
is attributable to the employment of a safe transfusion’s
screening policy with a very high decrease number of new
infections.
Recovery from acute infection is estimated to occur in
10–25% of patients, and the onset of the disease remains
largely unknown since it is symptomless in the vast majority
of cases. Moreover, since the availability of eﬀective therapies
has led to treat patients, the outcome and natural history of
untreated people in order to analyse the events, their tim-
ing, and type of evolution has not been fully evaluated [6–
12]. Furthermore, another essential phenomenon that has
hampered the diﬃculty to obtain reliable information of the
progression of the disease is because many cofactors can
change the rate of progression of the disease. In particular,
alcohol consumption together with other several factors
(iron overload, hepatic steatosis, metabolic syndrome, viral
coinfections) may play an important role in accelerating the
progression of the disease [13].
A wide range of study designs (i.e., case-series, cross-
sectional, case-control, cohort, clinical trial) has been devel-
oped in clinical investigation, and, among them, cohort
studies have been largely employed. This type of studies2 International Journal of Hepatology
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Figure 1: Natural history of chronic HCV infection.
represents a valid approach to by-pass the above-mentioned
diﬃculties to assess the natural history of HCV infection.
In fact, based on the statistical concept of “analysis by
segments,” a typical approach for the cohort studies, the
progression of HCV infection can be designed as the
sequence of diﬀerent, limited, and of presumably known
duration stages of the disease.
2.N aturalH ist o ryo fHCVI nf ectio n
2.1. Studies Estimating Disease Progression. To deﬁne the
natural history of an infectious disease, it is mandatory to
establish the time of infection, to deﬁne the onset of the
symptoms, to prospectively monitor expected end-points,
to record the occurrence of risk factors (alcohol, other
viruses, metabolic disorders, etc.), and to follow untreated
patients for a long period of time. Unfortunately, although
any possible HCV infection was demonstrable since 1989
[14], there is no hope to ﬁnd such data in the studies
published on this topic and a great heterogeneity among
them might be mostly due to the diversity in the design
of the studies themselves. In fact, in retrospective cohort
studies, the presence of cirrhosis was ascertained in 17% up
to55%ofchronicinfectedadults,andHCCin1%upto23%
[15, 16]; on the other hand, in prospective cohort studies,
the rate of progression to cirrhosis was of 7% to 16% and
H C Co f0 . 7 %t o1 . 3 %p e ry e a r[ 6, 17, 18]. In retrospective-
prospective cohort studies, the prognosis of patients with
chronic hepatitis C (CHC) was reported as benign and only
a minority of the infected subjects ultimately developed
cirrhosis [19, 20]. Similarly, Vogt and coworkers described
a low rate of liver disease occurrence in children who
underwentcardiacsurgerybeforetheimplementationsofthe
newrulesforblood-donorsscreening[21].Bycontrast,other
studies reported a relative high rate of cirrhosis [22, 23], and,
in particular, 5.9% of cirrhosis and liver-related death was
found in a small cohort of anti-HCV US military recruits
during a 45-year follow-up study [24].
2.2. Prognostic Factors of Disease Progression. A long-lasting
elevated necroinﬂammatory activity seems to play a crucial
role in the progression of the disease, and this clinical evi-
dence seems to be supported also by data from patients with
persistently normal ALT. Within this peculiar context, no
progression of the disease was found at a second liver biopsy
taken after 5 years of followup, with the exception of subjects
in which the occurrence of ﬂares-up seemed modifying the
benign course of the disease [25–27]. However, even if the
biochemistry is only partially indicative, no other reliable
marker able to predict the progression of the disease has
been identiﬁed so far. Moreover, the prognosis of subjects
infected by HCV can also be aﬀected by diﬀerent variables,
and many factors, either virus-related or host-related, have
been investigated in order to understand the natural history
of this infection.
2.3. Viral Factors. Regardless the evidence that genotype 1b
more than genotype 2 was reported to be associated with
the development of HCC [28]a n dw i t hap o o ro u t c o m eo f
the disease [28–30], no data are available, so far, about other
HCV genotypes. By contrast, while the viral load seems not
to be associated with the histology activity index, it has
relevant implications rather with viral response to therapy
[31–34]. The presence of other viral coinfections (i.e., HIV,
HBV) speeds up the clinical course of the disease [35, 36].
The coinfection with HBV is most common in several high-
risk populations, suchas injection drug users (IDU) [37, 38],
patients on hemodialysis [39], patients undergoing organ
transplantation [40], HIV-positive individuals [41, 42], and
β-thalassemia patients [43, 44]. In all these categories, liv-
er injury was more severe in terms of progression of ﬁ-
brosis and liver cirrhosis, hepatic decompensation [45–50].
Moreover in this subgroup has been shown an increased
risk of developing HCC [51–53]. Also, the presence of
HIV has a negative impact on the natural history of HCV
since the progression to cirrhosis is higher in coinfected
[54, 55]. HCV/HIV coinfection is associated to develop
other complications, such as hematologic disorders [56, 57],
kidney disease [58, 59], cardiovascular disease [60, 61], and
neurologic status [62–65].
2.4. Host Factors. Among the host-related factors, female
gender and young age seem to inﬂuence the outcome of
CHC [66]. In the last few years, another important aspect
represented by the presence of comorbidities was shown to
impact on the evolution of chronic HCV infection. Hepatic
steatosis, obesity, and/or an insulin resistance must be con-
sidered important determinants of the disease progression
[67–70]. Recent data also show that genotype 1 might spe-
ciﬁcally interfere with a peculiar host genetic background
conditioning an altered intracellular insulin signalling [71,
72]. However, the relationship between body mass, insulin
resistance, steatosis, and clinical outcomes is still complex.
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the modiﬁable risk factors for liver disease progression were
studied, and insulin resistance was strongly associated with
outcomes [73]. On the other hand, the signiﬁcance of both
iron overload and “occult” HBV infection remains still con-
troversial [74–77]. The iron overload plays an important
role. The complexity of the interplay between iron and
CHC is underscored by recent ﬁnding that mutations in
HFE, particularly the common H63D variation, while being
associated with higher hepatic and total body iron, is also
related to a signiﬁcantly higher likelihood of complete and
sustained responses to antiviral therapy [78]. A recent study
shows that stainable iron in hepatocytes and portal tract cells
is a predictor of progression and clinical and histological
outcomes in advanced chronic hepatitis C while chronic
administration low-dose of peginterferon did not improve
outcomes, nor iron variables [79].
2.5.ExternalFactors. Amonginvestigatedcofactors,thealco-
hol abuse is the most important one which can dramatically
changethecourseofthedisease.Persistentintake evenoflow
alcohol amount may seriously interfere with the progression
of the disease [80]. Alcohol consumption, even at low daily
intake, has been proposed as a risk factor for the progression
of liver disease in chronic HCV infection [81, 82]. Alcohol
consumption has a very signiﬁcant impact on both the his-
tologic and clinical progression of chronic HCV infection.
The mechanisms whereby alcohol enhances HCV infection
and histologic damage are still unclear [83].
Geographical diﬀerences in the evolution of chronic
HCV infection to cirrhosis should also be considered: in
USA, and Europe, this percentage is almost 15% (range
8%–24%), but in Japan it ranges between 30% and 46%.
Similarly, the percentage of evolution to HCC is 0.7%–1.3%
in Western countries, but signiﬁcantly higher in the Far East
and Japan where the rate ranges from 10% to 19% [84].
3. The NaturalCourse of
HCV-InducedCirrhosis
The natural history of HCV-induced chronic liver disease
remains poorly measurable. As discussed above, a practical
approach used to by-pass the above-mentioned diﬃculties
is represented by the “analysis by segments” [85–88]. All
these studies agreed that the development of HCC represents
the main cause of death in cirrhotic patients and male sex,
olderage,highalpha-fetoproteinlevels,andHBVcoinfection
were considered the main risk factors of development of
the tumor. Interestingly, some studies have also described
as risk of HCC occurrence the presence of oesophageal
varices [29, 89]. The presence of gastrooesophageal varices
is commonly considered an important risk factor of hepatic
decompensation, and certainly they are expression of portal
hypertension. Based on this assumption, the hypothesis
that explains the association between varices and HCC
development is based on the assumption that an impaired
regional blood ﬂow due to portal hypertension might
determine local hypoxia which stimulates the synthesis of
angiogenic factors [90]. Moreover, HCV genotype 1b was
recently conﬁrmed as a risk factor associated with HCC
development in a prospective study [91, 92]. Accordingly,
a biological plausibility has been recently provided showing
a possible interplay by HCV and a cellular oncosuppressor
determining a linkage between a mutated viral site and a
diﬀerent sensitive to damage-induced apoptosis [93].
Taking into account all the available information, pat-
terns of progression to cirrhosis are very diﬀerent: fast if it
occursinlessthan20years,intermediatein20–50years,slow
inmorethan50years.Moreover,insomepatients,thereisno
progression at all. The causes of this divergence in outcome
are still poorly understood. However, survival at 5 years is
reduced to 50% after an episode of decompensation [94–96].
Future studies on the natural history of HCV disease
should be aimed to identify patients with high risk of disease
progression and to assess the impact of therapy on disease
outcome.
4. The Impact of Antiviral Therapy on Natural
Courseof the Disease
Thelackofrandomisedstudieshampersareliableestimation
of the impact of antiviral treatment on the long-term
outcome of patients with HCV infection. Several cohort
studies, designed to assess the response to Interferon (IFN)
therapy in cirrhotic patients, documented a better prognosis
for patients who received IFN regardless of HCV-RNA
eradication. Two retrospective reports [97, 98]c o n ﬁ r m e d
these data, and altogether these studies have demonstrated
that sustained virological response (SVR) is signiﬁcantly
associated with a reduction of decompensation rate, HCC
occurrence, and liver-related mortality. Therefore, liver dis-
ease morbidity and mortality is dependent on successful
antiviral therapy, and peginterferon plus ribavirin is, at
present time, the treatment of choice before direct-acting
antivirals (DAAs) will be available [99].
4.1. Progression from Chronic Hepatitis C to Cirrhosis . The
assessment of histological activity and ﬁbrosis stage of liver
biopsies performed before and after antiviral treatment
remains the most reliable parameter to evaluate short-term
beneﬁt of viral clearance. In 487 Japanese patients who
underwent paired liver biopsy, samples obtained from 1 to
10 years apart showed a regression of ﬁbrosis related to SVR
[100]. Accordingly, other European studies by analyzing the
impact of SVR on the long-term clinical outcome of chronic
hepatitis C concluded that SVR was signiﬁcantly associated
withadecreaseinﬁbrosisscore[11,101–103]. More recently,
George et al. demonstrated in a large cohort that clinical,
virologic, biochemical, and histological outcomes of patients
followed up to 5 years after SVR are favourable, and recovery
of normal or nearly normal liver architecture is possible
[104].
The available literature on the likelihood of progression
to cirrhosis in treated patients is limited [105–117]. Once
SVR is achieved the histological progression is uncommon
(7 out of 1,662 treated patients with SVR) (Table 1). On the
contrary, in relapsers or nonresponder patients, the rate of4 International Journal of Hepatology
Table 1: Cumulative rate of development of cirrhosis in patients with HCV-related chronic hepatitis according to sustained viral response
(SVR); n/a: not available.
Author Reference Treated
patients
Followup
(years)
Rate of cirrhosis
after SVR
Rate of cirrhosis
in absence of
SVR
Marcellin et al. [105] 450 1–7.6 0/75 n/a
Sata et al. [106] 63 0.6–3.8 0/25 9/38 (23.7%)
Lau et al. [107] 10 10–13 0/5 2/5 (40.0%)
Camm` ae ta l . [ 108] 62 0.7–9 0/62 5/360 (1.3%)
Ajello et al. [109] 31 10 1/10 (10.0%) n/a
Morisco et al. [110] 191 4 0/39 12/115 (10.4%)
Gallego et al. [111] 79 4 0/11 33/87 (37.9%)
Giannini et al. [112] 36 1–6 0/15 3/21 (14.3%)
Shindo et al. [113] 250 8–11 0/67 62/183 (33.9%)
Swain et al. [114] 997 8 0/989 8/997 (0.8%)
Veldt et al. [115] 343 1.6 6/110 (5.5%) 3/15 (20%)
Ciancio et al. [116] 97 7 0/83 3/86 (3.5%)
Chavalitdhamrong and Tanwandee [117] n/a 3 0/171 27/171 (15.8%)
7/1,662 (0.42%) 162/2,078
(7.8%)
diseaseevolutiontocirrhosisismuchmorefrequent(162out
of 2,078).
4.2. Progression from Compensated to Decompensated Cir-
rhosis and Hepatocellular Carcinoma. Unsatisfactory SVR
rates have been attained in patients with cirrhosis when
usingtraditionalmonotherapyregimensofrecombinantIFN
alfa or peginterferon [118], and all clinical trials for drug
registration considered decompensated liver disease as an
exclusion criterion [119–122]. In these studies, SVR rates
were calculated by pooling together patients with diﬀerent
degree of hepatic ﬁbrosis, ranging from marginal bridging
ﬁbrosis to compensated cirrhosis. As a consequence, no
deﬁnite conclusion could be reached about the eﬃcacy and
safety of treatment in this cohort of patients. Nevertheless,
results emerging from these studies suggested that treatment
of patients with well-compensated HCV-induced cirrhosis
using PEG-IFN alfa-2b plus RBV may be considered a
reliableoption in “easyto treat”“genotypes” (2a/c,3a), while
in the “diﬃcult to treat” ones (1a, 1b and 4 genotype), the
results are not satisfactory. In this subgroup of patients, the
use of baseline and on-treatment predictors of response may
enhance virologic outcomes and reﬁnement of the regimens
investigated is warranted. Further studies are also needed
to develop treatment schedules for individual genotype
populations.
5. Summary
Natural history of HCV-related chronic hepatitis is condi-
tioned by virus features, coinfections, and host characteris-
tics. In particular, a peculiar genetic background of the host
by conditioning the occurrence of intracellular metabolic
derangements (i.e., insulin resistance) might contribute to
accelerate the rate of progression to cirrhosis and eventually
the occurrence of HCC. Likely, direct interplays between vi-
rus genotype and host genetic background might be hypoth-
esized at this level.
Morbidity and mortality in cirrhosis is primarily associ-
ated with complications of liver cirrhosis and HCC occur-
rence. Therefore, the main goal of therapy is to inhibit vi-
ral replication and decrease liver necroinﬂammation that di-
rectly relates to development of cirrhosis and HCC.
Among patients treated with IFN-based therapy, those
with SVR showed a signiﬁcant reduction of progression to
cirrhosis and development of HCC. However, a residual risk
of hepatocellular carcinoma still remains indicating the need
for careful followup using ultrasonography every six months
in cirrhotic patients, even in those showing persistently
normalALTandundetectableHCVRNAlevelsafterantiviral
therapy.
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